Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of cisplatin + gemcitabine + trastuzumab for HER2-overexpressing advanced urothelial carcinoma
2004-005241-36Phase 2Active
- Sponsor
- ACROSS Group
- Start
- May 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, gemcitabine and cisplatin in transitional cell carcinoma (TCC), sponsored by ACROSS Group. Primary endpoint: overall response rate. Started May 2006; status: active.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2004-005241-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005241-36.